Targeting a specific protein to treat advanced breast cancer that resists standard therapies
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
This study is looking at ways to help women with advanced estrogen receptor-positive breast cancer who haven't had success with regular treatments by exploring how a protein called STAT3 affects their cancer and testing new strategies to block it, which could lead to better treatment options for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10979142 on NIH RePORTER |
What this research studies
This research focuses on advanced estrogen receptor-positive breast cancer patients who have not responded to standard treatments. It investigates the role of a protein called STAT3, which is linked to cancer progression and resistance to therapies. The approach involves using a combination of existing treatments and new strategies to inhibit STAT3, potentially improving outcomes for patients who have limited options. The study aims to understand how targeting this protein can help overcome resistance and enhance treatment effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced estrogen receptor-positive breast cancer who have shown resistance to CDK4/6 inhibitors.
Not a fit: Patients with early-stage breast cancer or those who have not received CDK4/6 inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with advanced breast cancer who are resistant to current therapies.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Keyomarsi, Khandan — University of Tx Md Anderson Can Ctr
- Study coordinator: Keyomarsi, Khandan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.